Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
American Journal of Pharmaceutical Education|August 23, 2013
Team-based learning in US colleges and schools of pharmacyRondall E Allen, Jeffrey Copeland, Andrea S Franks, et al.Seminars in Cell & Developmental Biology|September 4, 2010
EGFR signaling in breast cancer: bad to the boneJohn Foley, Nicole K Nickerson, Seungyoon Nam, et al.Cancer Letters|March 15, 2003
A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell linesEric E Williams, Laurie J Trout, Richard M Gallo, et al.Cancer Research|August 3, 2007
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutationNadia Godin-Heymann, Ianthe Bryant, Miguel N Rivera, et al.Journal of Medicinal Chemistry|November 11, 2005
Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probesHenry F VanBrocklin, John K Lim, Stephanie L Coffing, et al.Growth Factors (Chur, Switzerland)|January 21, 2012
EGFR ligands exhibit functional differences in models of paracrine and autocrine signalingKristy J Wilson, Christopher Mill, Sydney Lambert, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 26, 2008
Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptorsJulie A Przybyla, Juan P Cueva, Benjamin R Chemel, et al.Oncogene|December 9, 2003
Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinaseStuart S Hobbs, Elizabeth M Cameron, Robert P Hammer, et al.Oncogene|December 6, 2002
Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activationStuart S Hobbs, Stephanie L Coffing, Ann T D Le, et al.Breast Cancer Research and Treatment|April 15, 2008
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrantThomas Frogne, Rikke V Benjaminsen, Katrine Sonne-Hansen, et al.Pageof 5